Company / EPS (Diluted)
Zenas BioPharma, Inc. EPS (Diluted) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$11.89
FY2025
5-year range
-$24.25 / -$11.89
FY2023-FY2025
Trend
+51.0%
vs FY2024
Sector context
#200 of 204
Health Care
What the data says
Among 204 Health Care companies, Zenas BioPharma, Inc. is in the bottom 2% for eps (diluted). Improved from $-24.25 to $-11.89 over the past 2 years.
Based on SEC 10-K filings.
-11.89 in FY2025.
Improved from $-24.25 to $-11.89 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 204This company -$11.89 Sector average -$0.89
▼
-1241.6% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 51.0% year-over-year.
- Ranks #200 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$11.89 | +51.0% |
| FY2024 | -$24.25 | +0.0% |
| FY2023 | -$24.25 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026